Drug repurposing offers a way to find new treatments using existing medications, but regulatory hurdles and financial disincentives often prevent progress. Mika Newton and Bob Battista examine the challenges of data sharing in the pharmaceutical industry, the high costs of clinical trials, and why companies hesitate to pursue niche indications. They also explore potential policy solutions that could encourage collaboration and make more life-saving treatments accessible to patients.